IGXT = MC $49 M / $13 M Cash / FDA Decision for Mi
Post# of 83
IGXT announced that the FDA has accepted the resubmission of 505(b)(2) new drug application (NDA) for Rizaport oral soluble film 10 mg, which is being developed for the treatment of acute migraine. The FDA has set an action date of Apr 1, 2019.
IntelGenx: A Small Cap With A Big Pipeline In Cannabis, Alzheimer's, And ED
https://seekingalpha.com/article/4208382-inte...heimers-ed
Presentation
http://s2.q4cdn.com/790425727/files/doc_prese...tation.pdf